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Abstract
One major hurdle to the success of adoptive T-cell therapy is the identification of antigens that 
permit effective targeting of tumors in the absence of toxicities to essential organs. Previous work 
has demonstrated that T cells engineered to express chimeric antigen receptors (CAR-T cells) 
targeting the murine homolog of the colorectal cancer antigen GUCY2C treat established 
colorectal cancer metastases, without toxicity to the normal GUCY2C-expressing intestinal 
epithelium, reflecting structural compartmentalization of endogenous GUCY2C to apical 
membranes comprising the intestinal lumen. Here, we examined the utility of a human-specific, 
GUCY2C-directed scFv as the basis for a CAR construct targeting human GUCY2C-expressing 
metastases. Human GUCY2C-targeted murine CAR-T cells promoted antigen-dependent T-cell 
activation quantified by activation marker upregulation, cytokine production, and killing of 
GUCY2C-expressing, but not GUCY2C-deficient, cancer cells in vitro. GUCY2C CAR-T cells 
provided long-term protection against lung metastases of murine colorectal cancer cells 
engineered to express human GUCY2C in a syngeneic mouse model. GUCY2C murine CAR-T 
cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C, 
providing durable survival in a human xenograft model in immunodeficient mice. Thus, we have 
identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the 
treatment of GUCY2C-expressing metastatic colorectal cancer.
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Introduction
Chimeric antigen receptor (CAR)-expressing T cells are effective in patients with advanced 
B-cell malignancies and neuroblastoma (1–3). However, the clinical utility of adoptively 
transferred T cells has been limited in patients with colorectal cancer, reflecting antigen “on-
target, off-tumor” toxicities limiting treatment options (4,5). Guanylyl cyclase C (GUCY2C) 
is a membrane-bound receptor that produces the second messenger cGMP following 
activation by its hormone ligands guanylin or uroguanylin, regulating intestinal homeostasis, 
tumorigenesis, and obesity (6). GUCY2C cell surface expression is confined to luminal 
surfaces of the intestinal epithelium and a subset of hypothalamic neurons (7). Its expression 
is maintained in >95% of colorectal cancer metastases and it is ectopically expressed in 
tumors that evolve from intestinal metaplasia, including esophageal, gastric, and pancreatic 
cancers (8,9). The inaccessibility of GUCY2C in the apical membranes of polarized 
epithelial tissue (10), due to subcellular restriction of GUCY2C, creates a therapeutic 
opportunity to target metastatic lesions of colorectal origin which have lost apical-
basolateral polarization (11), without concomitant intestinal toxicity. Previously, we 
demonstrated in a syngeneic, immunocompetent mouse model that CAR-T cells targeting 
murine GUCY2C were effective against colorectal cancer metastatic to lung in the absence 
of intestinal toxicities (12). Similarly, other GUCY2C-targeted therapeutics, including 
antibody-drug conjugates (13) and vaccines (14,15), are safe in preclinical animal models, 
and therapeutic regimens utilizing these platforms are in clinical trials for metastatic 
esophageal, gastric, pancreatic, and colorectal cancers (NCT02202759, NCT02202785, 
NCT01972737). The safety of these therapeutic regimens, in the context of GUCY2C 
expression across the rostral-caudal axis of intestine, reflects compartmentalized expression 
of GUCY2C, enriched in apical, but limited in basolateral, membranes of epithelial cells 
(16–19). Systemic radiolabeled imaging agents conjugated to GUCY2C ligand target 
GUCY2C-expressing metastases without localizing in intestine (10), confirming the mucosal 
compartmentalization of the receptor. Tumors express up to 10-fold greater amounts of 
GUCY2C, compared to normal epithelial cells (9,20), potentially creating a quantitative 
therapeutic window to discriminate receptor overexpressing tumors from intestinal 
epithelium (21) with low/absent GUCY2C in basolateral membranes (19).
Here, we identified a human GUCY2C-targeted CAR that could potentially be employed in 
patients with GUCY2C-expressing gastrointestinal malignancies. This CAR induced 
antigen-dependent T-cell activation, cytokine production, and cytolytic activity. Human 
GUCY2C-targeted CAR-T cells were effective against metastatic tumors in 
immunocompetent, syngeneic mouse models, as well as xenograft models of human 
colorectal cancer.
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Materials and Methods
Cell lines and reagents
CT26 and β-galactosidase–expressing CT26.CL25 mouse colorectal cancer cell lines and the 
human colorectal cancer cell lines T84 and SW480 were obtained from ATCC and large 
stocks of low-passage cells were cryopreserved. Cells were authenticated by the original 
suppliers and routinely authenticated by morphology, growth, antibiotic resistance (where 
appropriate), appropriate GUCY2C and β-galactosidase expression, and pattern of 
metastasis in vivo and routinely screened for mycoplasma using the Universal Mycoplasma 
Detection Kit (ATCC, Cat. No. 30-1012K). Before injection into mice, cells were routinely 
cultured for <2 weeks. The gene encoding human GUCY2C was codon-optimized 
(Supplementary Fig. S1) and synthesized (Gene Art, Life Technologies) and cloned into the 
retroviral construct pMSCVpuro (Clontech). CT26.hGUCY2C and CT26.CL25.hGUCY2C 
were generated by transducing CT26 and CT26.CL25 cells with retroviral supernatants 
encoding hGUCY2C, followed by selection with puromycin. Retroviral supernatants were 
produced by transfecting the Phoenix-Eco retroviral packaging cell line (Gary Nolan, 
Stanford University) with pMSCV-Puro (Clontech) or hGUCY2C-pMSCV-Puro and the 
pCL-Eco (Imgenex) retroviral packaging vector (12). Luciferase-containing T84.fLuc cells 
were generated by transduction with lentiviral supernatants generated by transfecting 293FT 
cells (Invitrogen) with pLenti4-V5-GW-luciferase.puro (kindly provided by Andrew Aplin, 
Thomas Jefferson University) and the ViraPower Lentiviral Packaging Mix (Invitrogen) 
according in manufacturer instructions, followed by selection in puromycin. The single 
chain variable fragment (scFv) from the human GUCY2C-specific antibody 5F9 
(Supplementary Fig. S2) was cloned into the pFUSE-rIgG-Fc2 (IL2ss) plasmid (Invivogen), 
producing a 5F9 scFv fusion protein with rabbit Fc (5F9-rFc). 5F9-rFc was collected in 
supernatants of transfected 293F cells (Life Technologies), titrated in ELISA plates (Nunc-
Immuno PolySorp) coated with BSA or recombinant 6xHis-tagged hGUCY2C extracellular 
domain (6xHis-hGUCY2CECD) protein purified under contract from HEK293-6E cells by 
GenScript and detected with HRP-conjugated goat anti-rabbit (Jackson ImmunoResearch). 
For flow cytometry, cells were stained with 5F9-rFc or control supernatants from un-
transfected 293F cells diluted in FACS buffer (1% heat-inactivated FBS in PBS), followed 
by secondary Alexa Fluor 488–conjugated anti-rabbit (Life Technologies) in FACS buffer. 
Cells were fixed with 2% paraformaldehyde (PFA; Affymetrix) and analyzed using the BD 
LSR II flow cytometer and FlowJo v10 software (Tree Star).
Murine CAR-T Cell Generation
Murine CAR components were employed to produce a third-generation, codon-optimized 
retroviral CAR construct as previously described (12). A codon-optimized scFv sequence 
derived from the 5F9 human GUCY2C-specific antibody (Supplementary Fig. S2) was 
cloned into a CAR construct containing murine sequences of the BiP signal peptide, CD8α 
hinge region, CD28 transmembrane and intracellular domains, and 4-1BB (CD137) and 
CD3ζ intracellular domains, producing the 5F9.m28BBz CAR construct (Supplementary 
Fig. S3). CARs derived from the human ERBB2 (Her2)-specific antibody 4D5 or mouse 
CD19-specific antibody 1D3 (Supplementary Fig. S2) were used as controls as indicated 
(Control m28BBz). CARs were subcloned into the pMSCV-IRES-GFP (pMIG) retroviral 
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vector (Addgene # 27490). The Phoenix-Eco retroviral packaging cell line (Gary Nolan, 
Stanford University) was transfected with CAR-pMIG vectors and the pCL-Eco retroviral 
packaging vector (Imgenex) using the Calcium Phosphate ProfectionR Mammalian 
Transfection System (Promega). Retrovirus-containing supernatants were collected 48 hours 
later, filtered through 0.45 μM filters, and aliquots were frozen at −80°C.
Murine CD8+ T cells were negatively selected from BALB/c splenocytes using the CD8α+ 
T cell Isolation Kit II and LS magnetic columns (Miltenyi Biotec). CD8+ T cells were 
subsequently stimulated with anti-CD3/anti-CD28–coated beads (T Cell Activation/
Expansion Kit, Miltenyi Biotec) at a 1:1 bead:cell ratio at 1x106 cells/mL in cRPMI with 
recombinant human IL2 (100 U/mL; NCI Repository). The day following stimulation, half 
of the culture media was carefully replaced with an equal volume of thawed retroviral 
supernatant in the presence of polybrene (8 μg/mL; Millipore). Spinoculation was performed 
at room temperature for 90 minutes at 2500 rpm followed by incubation at 37°C for 2.5 
hours, at which point cells were pelleted and resuspended in fresh media containing IL2 
(100 U/mL). T cells were expanded for 7–10 days by daily dilution to 1x106 cells/mL with 
fresh cRPMI and IL2 at which point they were used for functional assays.
Human CAR-T Cell Generation
For studies with human T cells, PBMCs were collected from consenting volunteers in 
accordance with regulatory and institutional requirements. MACS (Stemcell Technologies) 
purified CD8+ T cells were negatively selected from individual normal healthy donor whole 
blood at >90% purity. CAR domains employing human sequences were used to produce a 
third-generation, codon-optimized retroviral CAR construct containing the 5F9 human 
GUCY2C-specific scFv and human sequences of the GM-CSF signal peptide, CD8α hinge 
region, CD28 transmembrane and intracellular domains, and 4-1BB (CD137) and CD3ζ 
intracellular domains producing 5F9.h28BBz (Supplementary Fig. S4). CAR-encoding 
amphotropic γ-retrovirus production was similar to that with murine T cells, but replaced 
pCL-Eco with the pCL-Ampho packaging plasmid (Imgenex). Retroviral transduction 
occurred on day 3 or 4 post-activation with ImmunoCult CD3/CD28 Activator (Stem Cell 
Technologies). Cells underwent flow sorting for GFP-enrichment on day 7, followed by 
experimental use on day 10. Throughout the duration in culture, human CD8+ T cells were 
maintained in ImmunoCult-XF media (Stemcell Technologies) supplemented with 100 
U/mL recombinant, human IL2 (NCI Repository).
CAR Surface Detection
CAR-transduced T cells were stained with the LIVE/DEAD Fixable Aqua Dead Cell Stain 
kit (Invitrogen) in PBS, labeled with varying concentrations of 6xHis-hGUCY2CECD for 1 
hour in PBS 0.5% BSA, stained with anti-5xHis-Alexa Fluor 647 conjugate (Qiagen) and 
anti-CD8b-PE (clone H35.17.2, BD Biosciences) for 1 hour in PBS 0.5% BSA, fixed with 
2% PFA and analyzed using the BD LSR II flow cytometer and FlowJo software v10 (Tree 
Star). hGUCY2C binding was determined by mean fluorescence intensity of Alexa Fluor 
647 on live CD8+ CAR+ (GFP+) cells. Non-linear regression analysis (GraphPad Prism v6) 
was used to determine the Kav and Bmax of GUCY2C-CAR binding.
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Mouse T-cell Phenotyping, Activation Markers, and Intracellular Cytokine Staining
For phenotyping, 1x106 non-transduced or CAR-transduced mouse T cells were stained with 
LIVE/DEAD Fixable Aqua Dead Cell Stain kit (Invitrogen) in PBS and subsequently 
stained for surface markers using anti-CD8α–BV570 (clone RPA-T8; Biolegend), anti-
CD45RA–PerCP-Cy5.5 (clone 14.8; BD Biosciences), and anti-CD62L–PE-Cy7 (clone 
MEL-14; BD Biosciences) for 30 minutes in PBS 0.5% BSA. Cells were subsequently fixed 
and permeabilized (BD Cytofix/Cytoperm Kit; BD Biosciences) with Cytofix/Cytoperm 
buffer for 20 minutes at 4°C and stained for intracellular GFP (anti-GFP–Alexa Fluor 488; 
Invitrogen) for 45 minutes in Perm/Wash buffer to identify CAR-transduced cells. The 
following subsets were then quantified based on CD45RA and CD62L staining: Tn/scm 
(naïve or T memory stem cells; CD62L+CD45RA+), Tcm (central memory T cells; CD62L
+CD45RA−), Tem (effector memory T cells; CD62L−CD45RA−), and Temra (effector 
memory T cells expressing CD45RA; CD62L−CD45RA+).
For activation marker and cytokine analysis, 1x106 CAR-transduced mouse T cells were 
stimulated for 6 hours in tissue culture plates previously coated with 1 μg/mL GUCY2C in 
PBS overnight at 4°C or in tissue culture plates containing 1x106 CT26 or CT26.hGUCY2C 
cells. As a positive control, CAR-T cells were incubated for 6 hours with 1X Cell 
Stimulation Cocktail (PMA/Ionomycin, eBioscience). Incubation included 1X Protein 
Transport Inhibitor Cocktail (eBioscience) when assessing intracellular cytokines. Cells 
were stained with LIVE/DEAD Fixable Aqua Dead Cell Stain kit (Invitrogen) and 
subsequently stained for surface markers using anti-CD8α–PerCP-Cy5.5 (clone 53.6–7; BD 
Biosciences), anti-CD69–PE (clone H1.2F3; BD Biosciences), anti-CD25–PE (clone 
PC61.5, eBioscience), and anti-CD44–APC (clone IM7; Biolegend). Intracellular cytokine 
staining was performed using the BD Cytofix/Cytoperm Kit (BD Biosciences) and staining 
with anti-GFP–Alexa488 (Invitrogen), anti-IFNγ–APC-Cy7 (clone XMG1.2; BD 
Biosciences), anti-TNFα–PE-Cy7 (clone MP6-XT22; BD Biosciences), anti-IL2–APC 
(clone JES6-5H4; BD Biosciences) and αMIP1α–PE (clone 39624; R&D Systems). Cells 
were fixed in 2% PFA and analyzed on a BD LSR II flow cytometer. Analyses were 
performed using FlowJo v10 software (Tree Star).
Human T-cell Activation Marker and Intracellular Cytokine Staining
For activation marker and cytokine analysis, 1x106 human GUCY2C-directed CAR-
transduced human T cells were stimulated for 6 hours in tissue culture plates coated 
overnight at 4°C with 10 μg/mL human GUCY2C or BSA control antigen in PBS or with 
1X Cell Stimulation Cocktail (PMA/Ionomycin, eBioscience) added at the time of plating 
CAR-T cells. All conditions included 1X Protein Transport Inhibitor Cocktail (eBioscience) 
at the beginning of the incubation period. Cells were stained with LIVE/DEAD Fixable 
Aqua Dead Cell Stain kit (Invitrogen) in PBS for 10 minutes and subsequently stained for 
surface markers using anti-CD8–Qdot 800 (clone 3B5, Invitrogen) and anti-CD69–APC 
(clone L78, BD Biosciences) in PBS 0.5% BSA for 25 minutes. Intracellular cytokine 
staining was performed using the BD Cytofix/Cytoperm Kit (BD Biosciences) consisting of 
fixation with Cytofix/Cytoperm buffer for 20 minutes and staining with anti-GFP–Alexa 
Fluor 488 (Invitrogen), anti-IFNγ–BV605 (clone 4S.B3; BioLegend), anti-TNFα–PerCP-
Cy5.5 (clone Mab11; BD Biosciences), and anti-IL2–PE (clone MQ1-17H12; BD 
Magee et al. Page 5
Cancer Immunol Res. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Biosciences) in BD perm wash buffer for 45 minutes. Cells were fixed in 2% PFA and 
analyzed on a BD LSR II flow cytometer. Analyses were performed using FlowJo v10 
software (Tree Star).
T-Cell Cytotoxicity Assays
The xCELLigence real-time, cell-mediated cytotoxicity system (Acea Biosciences Inc.) was 
utilized for assessment of CAR-T cell–mediated cytotoxicity as previously described (12). 
Briefly, 1x104 CT26 or CT26.hGUCY2C or 2.5x104 T84 or SW480 cancer cell targets were 
plated in 150 μL of growth medium in each well of an E-Plate 16 (Acea Biosciences) and 
grown overnight in a 37°C incubator, quantifying electrical impedance every 15 minutes 
using the RTCA DP Analyzer system and RTCA software version 2.0 (Acea Biosciences 
Inc.). Approximately 24 hours later for mouse and 6 hours for human T cell experiments, 50 
μL of CAR-T cells were added (5:1 E:T ratio for mouse T cells or 10:1 E:T ratio for human 
T cells), or 50 μL of media or 10% Triton-X 100 (Fisher) was added for a final (v/v) of 2.5% 
Triton-X 100 as negative and positive controls, respectively. Cell-mediated killing was 
quantified over the next 10–20 hours, reading electrical impedance every 15 minutes. 
Percent specific lysis values were calculated using GraphPad Prism Software v6 for each 
replicate at each time point, using impedance values following the addition of media and 
Triton-X 100 for normalization (0% and 100% specific lysis, respectively).
Alternatively, the β-gal release T-cell cytotoxicity assay utilized CT26 cancer cell targets 
expressing β-galactosidase (CT26.CL25). Cancer cell targets were plated at 2x105 cells/well 
in a 96-well plate and incubated with increasing effector CAR-T cell to cancer cell target 
ratios for 4 hours at 37°C. Released β-galactosidase was measured in the media using the 
Galacto-Light Plus System (Applied Biosystems, Carlsbad, California). Maximum release 
was determined from supernatants of cells that were lysed with supplied lysis buffer. % 
specific lysis = [(experimental release - spontaneous release)/(maximum release - 
spontaneous release)] x 100.
Metastatic Tumor Models
BALB/c mice and NSG (NOD-scid IL2Rγnull) mice were obtained from the NCI Animal 
Production Program (Frederick, MD) and Jackson Labs (Bar Harbor, ME), respectively. 
Animal protocols were approved by the Thomas Jefferson University Institutional Animal 
Care and Use Committee. In syngeneic mouse models, BALB/c mice were injected with 
5x105 CT26.hGUCY2C cells in 100 μL of PBS by tail vein injection to establish lung 
metastases. On indicated days, mice received a non-myeloablative dose of 5 Gy total body 
irradiation in a PanTak, 310kVe x-ray machine (12). Mice received the indicated dose of 
CAR-T cells produced from CD8+ BALB/c T cells in 100 μL of PBS by tail vein at the 
indicated time points. Mice were followed for survival or sacrificed on day 18 after cancer 
cell injection and lungs were stained with India Ink and fixed in Fekete’s solution for tumor 
enumeration (22).
For re-challenge experiments, naïve mice or mice cleared of established tumors by CAR-T 
cells (referred to as “surviving mice”) received one dose of 5x105 CT26 or CT26.hGUCY2C 
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via tail vein injection. Surviving mice were initially challenged 16–40 weeks prior to the re-
challenge experiment.
In human tumor xenograft models, NSG (23) mice (JAX stock #005557) were injected with 
2.5x106 T84.fLuc cells in 100 μL PBS via intraperitoneal injection. Mice received a dose of 
107 total (not sorted on CAR+) T cells produced from CD8+ BALB/c T cells in 100 μL PBS 
via intraperitoneal injection on day 14 after cancer cell inoculation. Tumor growth was 
monitored weekly by subcutaneous injection of a 250 μL solution of 15 mg/ml D-luciferin 
potassium salt (Gold Biotechnologies) in PBS and imaging after 8 minutes of exposure 
using the Caliper IVIS Lumina-XR imaging station (Perkin Elmer). Total radiance (photons/
second) was quantified using Living Image In Vivo Imaging Software (Perkin Elmer).
Results and Discussion
hGUCY2C CAR-T cells
A recombinant antibody (clone 5F9) specific for human GUCY2C (hGUCY2C) bound to 
purified hGUCY2C extracellular domain (Fig. 1A) and murine CT26 colorectal cancer cells 
engineered to express hGUCY2C, but not hGUCY2C-deficient CT26 cancer cells (Fig. 1B). 
The 5F9 scFv was used to generate a third-generation murine CAR construct (5F9.m28BBz) 
containing the BiP signal sequence, CD8α hinge region, and intracellular CD28, 4-1BB, and 
CD3ζ signaling moieties and inserted into a retroviral construct (Fig. 1C). Retroviruses 
encoding control m28BBz or 5F9.m28BBz CARs were used to transduce murine T cells 
with ~35–45% transduction efficiency, quantified by a GFP transduction marker (Fig. 1D). 
hGUCY2C-binding avidity (Kav = 11.2 nM) and CAR expression (Bmax = 957.8 MFI), 
quantified by incubating CAR-T cells with increasing concentrations of purified 6xHis-
tagged hGUCY2CECD followed by detection with labeled α5xHis antibody and assessment 
by flow cytometry, was comparable to CARs that exhibited functional reactivity to mouse 
GUCY2C (12) (Fig. 1D and E, Supplementary Fig. S5).
hGUCY2C CAR mediates T-cell activation and effector function
Transduction of purified mouse CD8+ T cells with control m28BBz or hGUCY2C-specific 
5F9.m28BBz CAR constructs had no impact on T-cell phenotype compared to non-
transduced cells (Fig. 2B), producing a mixture of memory and effector phenotypes [Tn/scm 
(CD62L+CD45RA+), Tcm (CD62L+CD45RA−), Tem (CD62L−CD45RA−), and Temra 
(CD62L−CD45RA+)] similar to other CAR constructs in CAR-T cells produced in the 
presence of IL2 (24). hGUCY2C-specific, but not control, CAR-T cells upregulated the 
activation markers CD25, CD69, and CD44 (Fig. 2C) and produced the effector cytokines 
IFNγ, TNFα, IL2, and MIP1α (Fig. 2D) when stimulated with immobilized hGUCY2CECD 
protein or CT26.hGUCY2C cells (Supplementary Fig. S6 and S7). Activation marker and 
cytokine responses were absent when 5F9.m28BBz CAR-T cells were stimulated with BSA 
or hGUCY2C-deficient CT26 cells, confirming that T-cell activation by the 5F9.m28BBz 
CAR is antigen-dependent (Fig. 2C–D, Supplementary Fig. S6 and S7). Although 
5F9.m28BBz CAR-T cells were inactive against hGUCY2C-deficient CT26 cells in vitro 
(Fig. 2E), they exhibited time-dependent killing of CT26.hGUCY2C cells, quantified by 
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employing an electrical impedance assay (Fig. 2E) and confirmed in a β-galactosidase 
release T-cell cytotoxicity assay (Supplementary Fig. S8).
hGUCY2C CAR-T cells oppose metastatic colorectal cancer
The endogenous immune system can induce immunosuppression in the tumor 
microenvironment and compete with adoptively transferred T cells for resources necessary 
for long-term persistence (25). In that context, lymphodepletive conditioning regimens, such 
as low-dose total body irradiation (TBI) or chemotherapies, enhance the efficacy of 
adoptively transferred T cells by eliminating immunosuppressive cells and reducing 
competition for homeostatic cytokines, including IL7 and IL15 (25,26). Here, we utilized an 
immunocompetent mouse model and a non-myeloablative dose of 5 Gy total body 
irradiation (TBI) to mimic clinical treatment regimens. Immunocompetent BALB/c mice 
received CT26.hGUCY2C cells by tail vein to produce lung metastases, followed 3 days 
later by TBI and increasing doses of mouse CAR-T cells (Fig. 3A). hGUCY2C-targeted 
5F9.m28BBz, but not control, CAR-T cells improved survival of mice at a dose of 107 T 
cells (Fig. 3A). This dose also was effective when administered 7 days after cancer cell 
inoculation (Fig. 3B), and a second dose administered on day 14 further increased median 
survival compared to a single dose on day 7 (>150 vs 93.5 days, p<0.05; Fig. 3C). Lungs 
collected 18 days after cancer cell inoculation (11 days after treatment) contained tumor 
nodules, confirming that control mice succumbed to lung metastases while 5F9.m28BBz 
CAR-T cell treatment eliminated macroscopic tumors (Fig. 3D). To determine if surviving 
mice exhibited persistent protection against hGUCY2C-expressing tumors, long-term 
survivors (161-282 days following initial cancer cell inoculation) were challenged with 
either parental CT26 or CT26.hGUCY2C cells by tail vein injection to examine hGUCY2C-
specific protection (Fig. 3E). CT26 tumors are known to harbor the gp70 envelope protein 
derived from murine leukemia virus that generates protective gp70-specific CD8+ T-cell 
responses in some vaccination regimens (27). Here, long-term surviving and naïve mice 
challenged with parental CT26 cancer cells exhibited identical death rates, indicating that 
long-term survivors did not produce a protective immune response to gp70 or other antigens 
expressed in CT26 cells (Fig. 3E). Conversely, long-term survivors were protected against 
CT26.hGUCY2C cancer cells compared to naïve control mice, indicating that 5F9.m28BBz 
CAR-T cells produce persistent protection against hGUCY2C-expressing tumors (Fig. 3E).
hGUCY2C CAR-T cells recognize human colorectal tumors
We next determined if hGUCY2C CAR-T cells recognized native hGUCY2C on human 
colorectal tumors. The recombinant hGUCY2C-specific antibody 5F9 stained hGUCY2C on 
the surface of GUCY2C-expressing T84 (Fig. 4A), but not GUCY2C-deficient SW480 
(Supplementary Fig. S9A), human colorectal cancer cells. Correspondingly, 5F9.m28BBz 
CAR-T cells lysed T84 (Fig. 4B), but not SW480 (Supplementary Fig. S9B), cancer cells in 
vitro in a time-dependent manner. Control CAR-T cells did not kill either human cancer cell 
type, indicating that killing was antigen-dependent (Fig. 4B and Supplementary Fig. S9B). 
Human T cells expressing a human 5F9 CAR construct (5F9.h28BBz) produced effector 
cytokines following GUCY2C stimulation and killed human colorectal cancer cells 
endogenously expressing hGUCY2C (Supplementary Fig. S10). Mouse T cells expressing 
hGUCY2C-specific (5F9.m28BBz), but not control, CAR effectively treated T84 human 
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colorectal tumor xenografts in a peritoneal metastases model (Fig. 4C–E). Together, these 
data indicated that hGUCY2C-specific CAR constructs produced with the 5F9 scFv can 
redirect T cel mediated killing of human colorectal tumors endogenously expressing 
hGUCY2C.
Adoptive T-cell therapies targeting colorectal tumor antigens have been limited by antigen 
“on-target, off-tumor” toxicities (4,5). We previously validated GUCY2C as a potential 
target for CAR-T cell treatment in a completely syngeneic mouse model in which CARs 
targeting mouse GUCY2C promoted antitumor efficacy in the absence of toxicities to the 
normal GUCY2C-expressing intestinal epithelium (12). Here, we produced a human 
GUCY2C-specific CAR from an antibody that is currently employed as an antibody-drug 
conjugate in clinical trials for GUCY2C-expressing malignancies (NCT02202759, 
NCT02202785) and demonstrated its ability to induce T-cell activation, effector function, 
and antitumor efficacy in both syngeneic and human colorectal tumor xenograft mouse 
models using murine T cells. CARs produced from the 5F9 scFv do not cross-react with 
murine GUCY2C (Supplementary Fig. S11), preventing quantification of intestinal toxicity 
in mouse models. Differences in the antigen-recognition domain of the CAR described here 
and the murine CAR previously described (12), as well as inherent differences between mice 
and humans, suggest caution in GUCY2C CAR-T cell administration to humans, despite 
murine GUCY2C CAR-T cell safety data (12). Thus, appropriate safety measures should be 
considered when translating the use of GUCY2C CAR-T cells into the clinic, including 
transient CAR expression by mRNA electroporation (28) or incorporation of suicide genes 
(29). Nevertheless, GUCY2C-targeted CAR-T cells are an attractive tool for the T-cell 
therapy armamentarium, a paradigm that is limited by the lack of suitable antigen targets 
(30). Following further
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Figure 1. Generation of human GUCY2C-specific CAR-T cells
(A) Recombinant 5F9 antibody was assessed by ELISA for specific binding to 
hGUCY2CECD or BSA (negative control) plated at 1 μg/mL. Two-way ANOVA; 
****p<0.0001. (B) Flow cytometry analysis was performed on parental CT26 mouse 
colorectal cancer cells or CT26 cells engineered to express hGUCY2C (CT26.hGUCY2C) 
and stained with 5F9 antibody. (C) Schematic of the third-generation murine CAR construct 
containing murine sequences of the BiP signal sequence, 5F9 scFv, CD8α hinge region, the 
transmembrane and intracellular domain of CD28, the intracellular domain of 4-1BB 
(CD137), and the intracellular domain of CD3ζ (5F9.m28BBz). The CAR construct was 
inserted into the MSCV retroviral plasmid pMIG upstream of an IRES-GFP marker. (D) 
Murine CD8+ T cells transduced with a retrovirus containing a control (1D3.m28BBz) CAR 
or CAR derived from the 5F9 antibody (5F9.m28BBz) were labeled with purified 6xHis-
hGUCY2CECD (10 μg/mL), detected with anti-5xHis-Alexa Fluor 647 conjugate. Flow plots 
were gated on live CD8+ cells. (E) 6xHis-hGUCY2CECD binding curves for 5F9-derived or 
control (1D3) CARs, gated on live CD8+GFP+ cells (Supplementary Fig. S5). Combined 
from 3 independent experiments.
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Figure 2. hGUCY2C-specific CARs mediate antigen-dependent T-cell activation and effector 
functions
(A–E) Murine CD8+ T cells were left non-transduced (None) or transduced with control 
1D3.m28BBz or 5F9.m28BBz CAR constructs as indicated. (A) Gating strategy for all 
analyses in B–D. (B) Representative CAR-T cell phenotyping plot based on CD45RA and 
CD62L. Two-way ANOVA; NS: not significant; Bars: mean ± SD from 2–3 independent 
experiments; Tn/scm: naïve or T memory stem cells; Tcm: central memory T cells; Tem: 
effector memory T cells; Temra: effector memory T cells expressing CD45RA. (C–D) 106 
CAR-T cells were stimulated for 6 hours with plate-coated antigen (BSA or hGUCY2C) or 
PMA and ionomycin (PMA/IONO). T-cell activation markers (CD25, CD69, or CD44) and 
intracellular cytokine production (IFNγ, TNFα, IL2, and MIP1α) were then quantified by 
flow cytometry. Graphs indicate the mean ± SD (C) activation marker upregulation (MFI) 
and (D) polyfunctional cytokine production (% of CAR+ cells) from 3 independent 
experiments. (E) Parental CT26 or CT26.hGUCY2C mouse colorectal cancer cells in an E-
Plate were treated with CAR-T cells (5:1 E:T ratio), media, or 10% Triton-X 100 (Triton), 
and the relative electrical impedance was quantified every 15 minutes for 10 hours to 
quantify cancer cell death (normalized to time=0). Percent specific lysis values were 
calculated using impedance values following the addition of media and Triton for 
normalization (0% and 100% specific lysis, respectively). Two-way ANOVA, B–E; *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.
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Figure 3. hGUCY2C CAR-T cells provide long-term protection in a syngeneic lung metastasis 
model
(A–E) BALB/c mice were injected with 5x105 CT26.hGUCY2C cells via the tail vein to 
establish lung metastases. Control (4D5.m28BBz) or 5F9.m28BBz CAR constructs were 
transduced into murine CD8+ T cells. (A) Mice were treated 3 days later with 5 Gy total 
body irradiation (TBI) followed by 106–107 5F9.m28BBz (N=7–8/group) or 107 control 
(N=6) CAR-T cells. (B) Mice were treated on day 3 (D3) or day 7 (D7) with 5 Gy TBI 
followed by 107 control (N=10/group) or 5F9.m28BBz (N=9–10/group) CAR-T cells. (C) 
Mice were treated on day 7 with 5 Gy TBI followed by 107 control (N=10) or 5F9.m28BBz 
(N=12) CAR-T cells on day 7 and day 14. (D) Mice treated on day 7 with 5 Gy TBI and 
PBS or 107 control or 5F9.m28BBz CAR-T cells were sacrificed on day 18, lungs stained 
with India ink, and tumors/lung enumerated. One-way ANOVA; *p<0.05. (E) Surviving 
mice from B and C treated with 5F9.m28BBz CAR-T cells or naïve mice were challenged 
with 5x105 CT26 (N=4–7/group) or CT26.hGUCY2C (N=7/group) cells (re-challenge 
occurred 16–40 weeks after initial challenge). Log-rank Mantel-Cox test, A–C and E; 
**p<0.01, ***p<0.001, ****p<0.0001. Up arrows indicate CAR-T cell treatment days. Each 
panel indicates an independent experiment.
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Figure 4. hGUCY2C CAR-T cells eliminate human colorectal tumor xenografts
(A) hGUCY2C expression on T84 human colorectal cancer cells was quantified by flow 
cytometry using the recombinant 5F9 antibody. (B–E) Control (1D3.m28BBz) or 
5F9.m28BBz CAR constructs were transduced into murine CD8+ T cells. (B) T84 colorectal 
cancer cells in an E-Plate were treated in duplicate with 5F9-m28BBz or control CAR-T 
cells (5:1 E:T ratio), media, or 10% Triton-X 100 (Triton), and the relative electrical 
impedance was measured every 15 minutes for 20 hours to quantify cancer cell death 
(normalized to time=0). Percent specific lysis values were calculated using impedance 
values following the addition of media and Triton for normalization (0% and 100% specific 
lysis, respectively). Two-way ANOVA; **p<0.01; representative of two independent 
experiments. (C–E) Immunodeficient NSG mice were injected with 2.5x106 luciferase-
expressing T84 colorectal cancer cells via intraperitoneal injection and were treated with 107 
control (N=5/group) or 5F9-m28BBz (N=4/group) CAR-T cells on day 14 by intraperitoneal 
injection. (C–D) Total tumor luminescence (photons/second) was quantified just prior to T-
cell injection and weekly thereafter. Two-way ANOVA; *p<0.05. (E) Mice were followed 
for survival. Log-rank Mantel Cox test; *p<0.05.
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